Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

NCT05125679 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Terminated (A strategic decision was made not to further execute the study. This decision was not based on a safety concern)

Conditions

Interventions

Sponsor

Janssen-Cilag Ltd.